Slide 1: Investor Presentation
Investor Presentation November 2016 BSE: 532523 │ NSE: BIOCON │ REUTERS: BION.NS │ BLOOMBERG: BIOS IN │ WWW.BIOCON.COM
Slide 2: Safe Harbor
Safe Harbor Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements.
Slide 3: Agenda
Agenda Biocon: Who are we? Highlights • Business Highlights • Financial Highlights Growth Segments • Small Molecules • Biosimilars • Branded Formulations • Novel Molecules • Research Services - Syngene Five Year Financial Summary Outlook 3
Slide 4: Who are we?
BS Biocon C: o = o — o ° £ S
Slide 5: Biocon: Asia's Leading Biopharma Company
Biocon: Asia’s Leading Biopharma Company Our Vision To enhance global healthcare through innovative and affordable biopharmaceuticals for patients, partners and healthcare systems across the globe 5
Slide 6: The Biocon Journey: A continuous evolution
The Biocon Journey: A continuous evolution Successful IPO, Biocon listed in India Poised for global impact Building the India Business An Enzymes Company with Biosimilar insulins and expertise in biologics People: 250 & Antibodies Revenue: ₹ 11,940 Million Revenue: ₹ 320 Million Target US$1bn in sal
Slide 7: Evolution of Key Innovations: Making a Difference
Evolution of Key Innovations: Making a Difference 1979 - First Indian company to manufacture and export enzymes to US and Europe 2001 - First Indian company to be approved by US FDA for the manufacture of lovastatin from solid state fermentation 2004 - First company worldwide to commercialize generi
Slide 8: Recent Business Highlights
Recent Business Highlights Marketing Authorization Application for biosimilar Pegfilgrastim, Trastuzumab and Insulin Glargine accepted for review by the European Medicines Agency. On track for filing biosimilar Adalimumab in FY17. Filed proposed biosimilar Trastuzumab with USDFA. Other planned US fi
Slide 9: Financial Highlights – Q2 & H1 FY17
Financial Highlights – Q2 & H1 FY17* All Figures in ₹ Million except % Particulars Q2 FY17 Q2 FY16 Growth H1 FY17 H1 FY16 Growth Revenue 9,925 8,186 21% 20,254 16,598 22% EBITDA 2,784 1,916 45% 5,824 4,200 39% Net Profit# 1,467 970 51% 3,133 2,210 42% R&D Expenses in P&L 650 572 14% 1,164 1,069 9% G
Slide 10: Segmental Sales – Q2 & H1 FY17
Segmental Sales – Q2 & H1 FY17* All Figures in ₹ Million except % Particulars Q2 FY17 Q2 FY16 Growth H1 FY17 H1 FY16 Growth Small Molecules 3,888 3,376 15% 8,097 6,767 20% Biologics 962 764 26% 2,183 1,479 48% Branded Formulations 1,366 1,192 15% 2,948 2,314 27% Licensing 328 16 1950% 500 654 -24% S
Slide 11: Business Segments
Bs Biocon Business Segments
Slide 12: Growth Verticals: Aligned with Shifting Paradigms
Growth Verticals: Aligned with Shifting Paradigms 1. (a) APIs and (b) Generic Formulations Small Molecules 5. Contract Research & 2. Exports of Insulins, Manufacturing MAbs & Other Biologics Research Biosimilars Services (Biologics & (Syngene) g. Insulins) Growth Verticals Novel Branded 4. Unlock Va
Slide 13: Small Molecule APIs
Small Molecule APIs Product Portfolio which leverages our core fermentation capabilities and have a high degree of complexity. Early mover in niche products at commercial scale. One of the largest producers of various fermentation based statins and immunosuppressant API in India and across the globe
Slide 14: Small Molecule Generic Formulations
Small Molecule Generic Formulations Nascent pipeline, to file ~15-20 dossiers in the next few years. Rosuvastation Calcium ANDA approved by USFDA, to launch shortly. Pipeline includes solid oral & parenteral products in both potent & non-potent categories of compounds. Product pipeline comprises of
Slide 15: Biosimilars
Biosimilars Marketing Authorization Application for biosimilar Pegfilgrastim, Trastuzumab and Insulin Glargine accepted for review by the European Medicines Agency. On track for filing biosimilar Adalimumab in FY17. Proposed biosimilar Trastuzumab filed with USFDA. Other planned US filings in FY17 f
Slide 16: Biosimilars: Growth through partnership
Biosimilars: Growth through partnership BIOCON MYLAN • Global-scale, complex biologics • Strength in Regulatory/ filings manufacturing capabilities strategy • Facilities accredited by • Strong commercialization international regulatory agencies capability in US and EU. • Decade-long experience & • M
Slide 17: Global Biosimilars Pipeline – US$60 bn opportunity
Global Biosimilars Pipeline – US$60 bn opportunity Market Size* Molecule Type Status (US$ bn) Rh Insulin Recombinant Human Insulin EU Phase III complete 3.1 INSULINS Global Phase III, filed in EU. US filing Glargine Long Acting Basal Insulin 7.1 in FY17 Aspart Rapid Acting Insulin Analog Preclinical
Slide 18: Biosimilar Pipeline: Biocon well placed in the competitive landscape
Biosimilar Pipeline: Biocon well placed in the competitive landscape Molecule Biosimilar Development Pipeline@ Pre-Clinical Phase I Phase III/Filed Approved/ Marketed pegfilgrastim Pfizer Dr. Reddy’sBiocon-EMA, Apotex - FDA, EMA; Coherus - FDA, Richter – EMA, Sandoz – EMA Trastuzumab Oncobiologics,
Slide 19: Biosimilars Manufacturing: Building Global Scale
Biosimilars Manufacturing: Building Global Scale Biocon Malaysia: Asia’s largest integrated insulins manufacturing facility Biocon’s First Manufacturing expansion overseas in Iskandar, Johor. Investment of over US$250mn in the first phase. Emerging market filings underway. Expected commercialization
Slide 20: Branded Formulations
Branded Formulations • A Specialty Business with regional ambitions, currently in India and UAE. Planned expansions into markets of Sri Lanka and Malaysia in the coming quarters. • Strategy focused around biologics and differentiated products as anchor brands. • The UAE business sells Branded generi
Slide 21: Novel Molecules - Pipeline & Therapeutic Area Focus
Novel Molecules - Pipeline & Therapeutic Area Focus Insulin Tregopil (formerly IN-105)* Phase II Ready DIABETES T1D/ T2D First-in-Class Oral, Prandial Insulin Itolizumab* Phase I Ongoing Novel, humanized CD6 Antibody BVX-20# IND Ready Novel, humanized CD20 Antibody INFLAMMATION QPI-1007$ Phase III I
Slide 22: Novel Molecules – Progressing to key milestones
Novel Molecules – Progressing to key milestones Asset Details Tregopil Oral, Ultra Rapid-Acting Prandial Insulin: Phase II Ready Post- prandial glycemic control; Liver specific- portal delivery, Weight neutral Positive Phase I study data – DDI, Food Effect, PK/PD Data available Phase I studies p
Slide 23: Syngene (Research Services Business)
Syngene (Research Services Business) Global High Growth CRO Company Attractive Blue Chip Customer Base • One of the leading India-based contract • Highly successful track-record in research organizations (CRO) molecule development • Integrated discovery and development • Client base includes 8 of th
Slide 24: Five Year Financials & Outlook
Five Year Financials & Outlook 24
Slide 25: Financial Performance Summary (FY12-16)
Financial Performance Summary (FY12-16)# All Figures in ₹ Million except EPS Business Segment FY12 FY13 FY14 FY15 FY16 Biopharmaceuticals 16,764 18,705 21,382 22,367 23,908 - Biopharma 14,170 15,231 17,468 18,071 19,534 - Branded Formulations 2,594 3,474 3,914 4,296 4,374 Contract Research 4,101 5,5
Slide 26: Aspiring for $1 Billion in Revenues by FY 2018-19
Aspiring for $1 Billion in Revenues by FY 2018-19 Key Focus Areas o Small Molecules & Generic Formulations - Improved product mix incl. ANDAs o Biosimilars - Meaningful near term growth to be driven 25% by emerging markets, ramp up post developed market entry 30% o Branded Formulations –Strategy foc
Slide 27: Appendix
BS Biocon 2s os < ® 2. 2. <x
Slide 28: Business Holdings Structure
Business Holdings Structure Biocon Limited, India Small Molecules & ANDA Biocon Pharma, India (100%) Branded Formulations Biocon Pharma, US (100%) Biocon FZ LLC (100%)/ NeoBiocon, UAE (49%) Biocon Biologics, UK Biocon SA, Switzerland Syngene, India (100%) (100%) (73.54%)* Biocon Sdn Bhd, Biocon MAb
Slide 29: For further information, please visit www.biocon.com
For further information, please visit www.biocon.com Investor Relations contact: Saurabh Paliwal Tel : +91 80 6775 2040 Email: saurabh.paliwal@biocon.com